Chung SJ, Fung HL Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther. 1990 May;253(2):614-9.
Feelisch M, Kelm M Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun. 1991 Oct 15;180(1):286-93.
Gómez Ponce de León R, Wing D, Fiala C Misoprostol for intrauterine fetal death. Int J Gynaecol Obstet. 2007 Dec;99 Suppl 2:S190-3. Epub 2007 Oct 24. Review.
Hofmeyr GJ, Gülmezoglu AM, Pileggi C Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD000941. doi: 10.1002/14651858.CD000941.pub2. Review.
Hsieh FY, Lavori PW Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000 Dec;21(6):552-60.
Hughes EG, Kelly AJ, Kavanagh J Dinoprostone vaginal insert for cervical ripening and labor induction: a meta-analysis. Obstet Gynecol. 2001 May;97(5 Pt 2):847-55.
Ignarro LJ Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. Semin Hematol. 1989 Jan;26(1):63-76. Review.
Koopmans L, Wilson T, Cacciatore J, Flenady V Support for mothers, fathers and families after perinatal death. Cochrane Database Syst Rev. 2013 Jun 19;6:CD000452. doi: 10.1002/14651858.CD000452.pub3. Review.
Lokugamage AU, Forsyth SF, Sullivan KR, El Refaey H, Rodeck CH Randomized trial in multiparous patients: investigating a single vs. two-dose regimen of intravaginal misoprostol for induction of labor. Acta Obstet Gynecol Scand. 2003 Feb;82(2):138-42.
Michel T, Smith TW Nitric oxide synthases and cardiovascular signaling. Am J Cardiol. 1993 Sep 9;72(8):33C-38C. Review.
Murad F Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. Adv Pharmacol. 1994;26:19-33. Review.
Neiger R, Greaves PC Comparison between vaginal misoprostol and cervical dinoprostone for cervical ripening and labor induction. Tenn Med. 2001 Jan;94(1):25-7.
Nicoll AE, Mackenzie F, Greer IA, Norman JE Vaginal application of the nitric oxide donor isosorbide mononitrate for preinduction cervical ripening: a randomized controlled trial to determine effects on maternal and fetal hemodynamics. Am J Obstet Gyneco
Rådestad I, Steineck G, Nordin C, Sjögren B Psychological complications after stillbirth--influence of memories and immediate management: population based study. BMJ. 1996 Jun 15;312(7045):1505-8.
Rapoport RM, Draznin MB, Murad F Endothelium-dependent vasodilator-and nitrovasodilator-induced relaxation may be mediated through cyclic GMP formation and cyclic GMP-dependent protein phosphorylation. Trans Assoc Am Physicians. 1983;96:19-30.
Schmidt HH, Lohmann SM, Walter U The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta. 1993 Aug 18;1178(2):153-75. Review.
Silver RM, Heuser CC Stillbirth workup and delivery management. Clin Obstet Gynecol. 2010 Sep;53(3):681-90. doi: 10.1097/GRF.0b013e3181eb3297. Review.
Titiz H, Wallace A, Voaklander DC Manual removal of the placenta--a case control study. Aust N Z J Obstet Gynaecol. 2001 Feb;41(1):41-4.
Urquhart DR, Templeton AA The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Hum Reprod. 1990 Oct;5(7):883-6.
World Health Organization Induction and augmentation of labour. In: WHO, UNFPA, UNICEF, World Bank, editor. Managing Complications in Pregnancy and Childbirth: A Guide for Midwives and Doctors. Geneva: WHO; 2000. pp. 17-25.
Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
